Digital rectal examination, prostate-specific antigen and transrectal sonography (TRS) are the main diagnostic tools for evaluating men at risk for carcinoma of the prostate (PCa). PCa has a hypoechoic echo pattern via TRS in 60-85% of cases. Hypoechoic areas are observed, however, in benign prostatic hyperplasia (BPH) as well. For this reason, TRS yields a low specificity and sensitivity in detecting PCa in screening programs. Additional data, independent of the grey scale information available via TRS, can be obtained by using the innovative technology of color Doppler sonography. This imaging modality allows simultaneous real-time sonographic visualization and evaluation of vascular structures. The present study analyzes to what extent the analysis of blood flow perfusion of prostatic parenchyma can provide further information concerning the pathologic alterations occurring in abnormal prostate tissue. Blood flow phenomena were reproducibly demonstrated in the prostate and in the periprostatic tissue with the color-coded Doppler sonography (CD-TRS). 31 patients with the diagnosis of BPH could be separated into two different groups according to the findings with TRS and CD-TRS. In contrast, patients with histologically proven PCa (n = 16) had subjectively increased perfusion rates. Blood flow phenomena were analyzed using computer-calculated resistive index and pulsatility index as evaluations of flow and frequency. A preliminary analysis of the wave-form characteristics shows that flow in the prostate gland is associated with a high resistive index in both PCa and BPH. The mean frequency demonstrated in the pulsatility index appears to be high in PCa, but low in BPH cases. Further studies are needed to verify the described factors’ abilities to differentiate prostate tissue as either PCa or BPH.

Keywords:
Color-coded Doppler sonography, Benign prostatic hyperplasia, Prostate carcinoma
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.